| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Molecular Genetics and Cell Biology, Oncology Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543
The human von Hippel-Lindau disease (VHL) gene has recently been identified and, based on the nucleotide sequence of a partial cDNA clone, has been predicted to encode a novel protein with as yet unknown functions [F. Latif et al., Science (Washington DC), 260: 1317–1320, 1993]. The length of the encoded protein and the characteristics of the cellular expressed protein are as yet unclear. Here we report the cloning and characterization of a mouse gene (mVHLh1) that is widely expressed in different mouse tissues and shares high homology with the human VHL gene. It predicts a protein 181 residues long (and/or 162 amino acids, considering a potential alternative start codon), which across a core region of 
140 residues displays a high degree of sequence identity (98%) to the predicted human VHL protein. High stringency DNA and RNA hybridization experiments and protein expression analyses indicate that this gene is the most highly VHL-related mouse gene, suggesting that it represents the mouse VHL gene homologue rather than a related gene sharing a conserved functional domain. These findings provide new insights into the potential organization of the VHL gene and nature of its encoded protein.
1 Contributed equally to this work.
2 To whom requests for reprints should be addressed, at Department of Molecular Genetics and Cell Biology, Oncology Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, P. O. Box 4000, Princeton, NJ 08543.
Received 6/22/94. Accepted 1/ 6/95.
This article has been cited by other articles:
|
|
 |
|
  H. Murata, N. Tajima, Y. Nagashima, M. Yao, M. Baba, M. Goto, S. Kawamoto, I. Yamamoto, K. Okuda, and H. Kanno Von Hippel-Lindau Tumor Suppressor Protein Transforms Human Neuroblastoma Cells into Functional Neuron-like Cells Cancer Res., December 1, 2002; 62(23): 7004 - 7011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang and W. G. Kaelin Jr. Molecular Pathogenesis of the Von Hippel-Lindau Hereditary Cancer Syndrome: Implications for Oxygen Sensing Cell Growth Differ., September 1, 2001; 12(9): 447 - 455. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Iliopoulos, M. Ohh, and W. G. Kaelin Jr. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation PNAS, September 29, 1998; 95(20): 11661 - 11666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schoenfeld, E. J. Davidowitz, and R. D. Burk A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor PNAS, July 21, 1998; 95(15): 8817 - 8822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Gnarra, J. M. Ward, F. D. Porter, J. R. Wagner, D. E. Devor, A. Grinberg, M. R. Emmert-Buck, H. Westphal, R. D. Klausner, and W. M. Linehan Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice PNAS, August 19, 1997; 94(17): 9102 - 9107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Duan, A Pause, W. Burgess, T Aso, D. Chen, K. Garrett, R. Conaway, J. Conaway, W. Linehan, and R. Klausner Inhibition of transcription elongation by the VHL tumor suppressor protein Science, September 8, 1995; 269(5229): 1402 - 1406. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
